IN SUMMARY: Novartis will price its new Mayzent multiple sclerosis drug at 88,000 dollars per year which is more proof that pharma companies could care less about the heated debate around drug pricing.Continue reading
- Lilly says the net price for its Humalog insulin—the price after discounts and rebates—fell to an average of $135 a patient a month in 2018, from $147 in 2014. During the same period, the product’s average list price rose 51.9% to $594 per patient monthly.
- Lilly hasn’t raised the U.S. list price for Humalog since May 2017. U.S. sales of the drug rose 4% to $1.79 billion in 2018, which Lilly said was primarily driven by demand.
- Dug middlemen continue to take a huge chunk of prescription drug profits.
- American consumers regularly pay two to six times more for the same drugs as people abroad, but the United States spends some of the lowest amounts of its total healthcare on prescription drugs relative to other developed nations.
- By law, Medicare cannot engage in pharmaceutical negotiations for prices.
- PhRMA cites that on average, it takes more than 10 years and $2.6 billion dollars to bring a drug to market but these costs may be overstated.
- This administration doesn’t understand how our healthcare system really works.
- Employee’s are once again getting hit with more of the costs of their coverage in the form of higher premiums and higher deductibles.
- Health care premiums continue to take up more of employees’ paychecks.
- Just over a quarter of all covered employees are enrolled in policies with a deductible of at least $2,000, up from 22 percent last year and 15 percent five years ago.
- Worldwide obesity has nearly tripled since 1975, according to the World Health Organization. In 2016, more than 600 million adults were obese — or about 13 percent of the world’s population leading to a jump in cancer cases and other costly health conditions. Continue reading
- Despite Trump’s plan to lower drug prices companies still hiked prices far more often than they cut them. This year through the end of July, there were 4,412 brand-name drug price increases and 46 price cuts, a ratio of 96-to-1.
- Pharma continues to try and confuse the issue of drug pricing by blaming hospitals and PBM’s.
Fair, or not, pharma is going to continue to come under fire because of high drug prices, but what’s missing is the key fact that even if controls were implemented for prescription drug prices our health care costs would still be escalating. Here is a presentation on high drug prices with some sobering statistics. Continue reading
KEY TAKEAWAY: Mr Trump’s plan to curtail drug prices was long on slogans and short on substance. To understand who the winners were just follow the money via Wall Street.